Targeted Drug, Broad Questions: Clovis' Rociletinib Faces Scrutiny On Efficacy, Safety, Dosing

FDA's Oncologic Drugs Advisory Committee to opine on whether the tyrosine kinase inhibitor should come to market under accelerated approval now or await results from an ongoing Phase III confirmatory trial.